Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI-generated summary accurately and completely reflects the provided FDA label content for the boxed warning and warnings regarding fetal toxicity, including trimester-specific risk and discontinuation instructions when pregnancy is detected.
Category Scores
Accurate Statements
The label includes a boxed warning (Pregnancy category D) stating that use of drugs acting on the renin-angiotensin system during the second and third trimesters reduces fetal renal function and increases fetal/neonatal morbidity and death.
BOXED WARNING — FETAL TOXICITY (label text provided in prompt)
When pregnancy is detected, discontinue lisinopril and hydrochlorothiazide tablets as soon as possible.
BOXED WARNING — FETAL TOXICITY; WARNINGS — Fetal Toxicity (label text provided in prompt)
The warnings section states that ACE inhibitors can cause injury and even death to the developing fetus, and reiterates discontinuation of lisinopril and hydrochlorothiazide tablets as soon as possible when pregnancy is detected.
WARNINGS — Fetal Toxicity (label text provided in prompt)
The warnings continuation includes management/monitoring details such as serial ultrasound examinations, discontinuation if oligohydramnios is observed (unless lifesaving for mother), and close observation of infants for hypotension, oliguria, and hyperkalemia.
WARNINGS — Fetal Toxicity (continued; management and monitoring) (label text provided in prompt)
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
No incorrect or unsafe fetal-toxicity claims were introduced; the summary aligns with the provided boxed warning and warnings content, including discontinuation guidance upon pregnancy detection.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement